RecruitingNCT03253536

Prospective Observational Trial to Evaluate Quality of Life After Stereotactic Ablative Radiation Therapy in Patients With Hepatocellular Carcinoma

Sponsor

Ludwig-Maximilians - University of Munich

Enrollment

100 participants

Start Date

Jul 10, 2017

Study Type

OBSERVATIONAL

Conditions

Quality of Life Hepatocellular Cancer Stereotactic Body Radiation Therapy Observational

Summary

Prospective single arm, single center observational study to evaluate Quality of Life (Qol) after stereotactic body radiotherapy for patients with hepatocellular cancer. Patients will receive work-up, treatment and follow-up exclusively as routinely done except additional quality of life measurements. Qol will be measured by standardized and validated EORTC questionaires at different time points during routine follow-up.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is tracking quality of life in liver cancer patients who receive a precise, targeted form of radiation called stereotactic body radiation therapy (SBRT), where a few high-dose beams are aimed directly at the tumor. **You may be eligible if...** - You have been diagnosed with liver cancer (hepatocellular carcinoma) confirmed by a tissue biopsy or imaging - You have 1 to 3 liver tumors suitable for targeted radiation therapy, as determined by your medical team - You are 18 or older and able to complete questionnaires about your quality of life **You may NOT be eligible if...** - You are under 18 - You have already received systemic (whole-body) treatment for liver cancer - You are currently receiving other cancer treatments - Your cancer has spread to distant organs (metastases outside the liver) - You are unable to give informed consent Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.